Magdalena Kegel,  —

PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved in the combo all have different ways to attack the cancer, allowing better results than individual therapies, according to PharmaMar. Aplidin, compared to most cancer treatments, does…

Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade (bortezomib) with dexamethasone — information that Amgen, which makes Kyprolis, hopes to include in the treatment’s prescription label. The company has applied to both the U.S. Food and Drug Administration and the…

Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through bone marrow or stem cell transplants, has responded well to the treatment, with more than 70 percent of participants having a partial or complete response.

The U.S. Food and Drug Administration (FDA) has ordered Merck to suspend two Phase 3 and part of a Phase 1 clinical trials in which Keytruda (pembrolizumab) is tested in combination with the drugs Pomalyst (pomalidomide) or Revlimid (lenalidomide) for multiple myeloma.

The U.S. Food and Drug Administration (FDA) recently approved a lab test to aid in the detection and diagnosis of myeloma and a range of other blood cancers. The ClearLLab Reagents test now becomes the first FDA-authorized assessment for use with a method called flow cytometry to detect blood cancers, including…

Oncology Venture has enrolled the first patient into a Phase 1/2 trial of its compound APO010 in multiple myeloma. Patients in the study will be pre-screened using a drug response predictor tool, which indicates they are likely to respond to the treatment. This companion diagnostic, which the company calls…

GlycoMimetics’ GMI-1271 restored the punch of the myeloma treatment Velcade (bortezomib) in mice, which should rekindle hope in patients who failed to respond to Velcade, a study reports. GMI-1271, which is being tested in clinical trials, blocks E-selectin, an adhesion molecule associated with aggressive myeloma and resistance to Velcade. Another…

Janssen Biotech will discuss at a Chicago cancer conference the effectiveness of new multiple myeloma treatment combinations that include its therapy Darzalex (daratumumab). The United States and European Union approved some combinations of Darzalex and other therapies in 2016, but Janssen wanted to evaluate additional combinations. Janssen will present…

Treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD), in addition to a stem cell transplant, improved progression-free survival among multiple myeloma patients compared to RVD alone. But a recent Phase 3 trial (NCT01191060) demonstrated that this benefit did not translate to better overall survival at four…

A rabbit virus slowed the growth of multiple myeloma in mice, and eradicated the cancer in a fourth of the animals, a study reported. But researchers cautioned that the road to using the virus in humans would be long and uncertain. An advantage that a virus would have over chemotherapy…